However, initial clinical studies of IGF-1R antagonists as a single agent have not yielded satisfactory results, suggesting that multiple pathways inherent in NB may explain the varying treatment sensitivity and drug resistance in NB patients. Here, IGF1R is linked to neuroblastoma.